Loading…
Fierce Drug Dev Forum 2019 has ended
Monday, October 28 • 4:00pm - 4:45pm
Consider the Risk Profile Associated With Different Sources and Mechanisms of Financing

Sign up or log in to save this to your schedule and see who's attending!

  • Explore traditional, private, and alternative sources of investment
  • Outline the pros and cons for each finance mechanism and determine the best fit based on a company’s long-term goals
  • Gain insight on how each investor views risk and what makes them nervous when determining an investment opportunity


Speakers
avatar for Rahul Dhanda

Rahul Dhanda

CEO and President, SHERLOCK BIOSCIENCES
Rahul K Dhanda is a founder and is the president and chief executive officer of Sherlock Biosciences. He also serves on the company’s Board of Directors. Most recently, Mr. Dhanda spent 10 years at T2 Biosystems where he helped grow the company from an early-staged, venture-backed... Read More →
avatar for Neil Dhawan

Neil Dhawan

CEO, TRILOGY SCIENCES
Neil is currently working on developing new chemical biology approaches to build small and large molecule oncology drugs. Neil previously co-founded Dual Therapeutics, a venture-backed biotechnology company creating novel multi-pathway inhibitors for cancer treatment. Neil co-invented... Read More →
avatar for Douglas M. Fambrough, III, Ph.D.

Douglas M. Fambrough, III, Ph.D.

Chief Executive Officer, DICERNA PHARMACEUTICALS
Doug is co-Founder, President & CEO of Dicerna Pharmaceuticals, a second generation RNA interference company developing therapeutics for rare diseases and other liver diseases. Prior to taking the CEO role at Dicerna, Doug was a General Partner with the venture capital firm Oxford... Read More →
avatar for Roopom Banerjee

Roopom Banerjee

Chief Business Officer,, GLYMPSE BIO


Monday October 28, 2019 4:00pm - 4:45pm